Table 2.
Micronucleus frequency and cytokinesis-block proliferation index in human lymphocytes treated with ZnO nanomaterials
| Test substance | Treatment | BN cells scored | Distribution of BN cells according to the no. of MN | MN ± SH (%) | CBPI ± SH | |||
|---|---|---|---|---|---|---|---|---|
| Period (h) | Dose (μg/mL) | (1) | (2) | (3) | ||||
| Control | 48 | 0 | 2,000 | 6 | – | – | 0.30 ± 0.12 | 2.02 ± 0.044 |
| MMC | 48 | 0.20 | 2,000 | 68 | 8 | 4 | 0.48 ± 0.01 | 1.10 ± 0.035 |
| ZnO | 48 | 1 | 2,000 | 9 | 1 | – | 0.55 ± 0.17 | 2.11 ± 0.048 |
| 2 | 2,000 | 11 | 1 | – | 0.65 ± 0.18 | 1.63 ± 0.032 | ||
| 5 | 2,000 | 9 | 2 | – | 0.65 ± 0.18 | 2.05 ± 0.046 | ||
| 10 | 2,000 | 16 | 1 | 1 | 1.05 ± 0.23** | 2.05 ± 0.046 | ||
| 15 | 2,000 | 16 | – | – | 0.80 ± 0.20* | 2.05 ± 0.046 | ||
| 20 | 2,000 | 13 | – | – | 0.65 ± 0.18 | 2.08 ± 0.045 | ||
(1), (2), (3) BN cells with one, two, three MN, respectively
BN binucleate, MN micronucleus, CBPI cytokinesis-block proliferation index
* Significant from the control P < 0.05 (z test)
** Significant from the control P < 0.001 (z test)